The current study also demonstrated that the downregulation of LHX9 could inhibit glycolytic metabolic reprogramming and malignant biological features of GCSCs by reducing PDK1, LDHA, GLUT1, and HK2 levels, thereby delaying GC progression [38]. The gene discussed is SLC2A1; the disease is gastric cancer.